Notably, AREG gene expression varies with genetic background and immune system status, indicating that screening for AREG overexpression in patients before treatment could enhance the success rate of AREG inhibitors in IPF therapy [45]. The gene discussed is AREG; the disease is idiopathic pulmonary fibrosis.